Most of the U.S. Department of Justice’s major pharma-related decisions invoking the False Claims Act recently have involved illegal marketing and sales. So far, GSK’s is the only one to deal with current good manufacturing practices (cGMP’s).
The blockbuster model is dying a very slow and painful death and there will be more collateral damage before it's all over. Early morning brought news that Pfizer might buy Wyeth Pharmaceuticals, including its biologics division, for $60 billion.
I thought the whole "Rost for FDA Chief" that surfaced after John Mack's recent poll was a joke, but then read that Dr. Rost, who emerged as the favorite candidate in that poll, has received the backing of at least two members of Congress.
Several names are being bandied about as leading candidates for the position of FDA commissioner in the Obama adminstration. They include Duke University's Robert Califf, Cleveland Clinic's Steven Nissen, Baltimore health commissioner Joshua Sharfstein, and George Washington U. professor Susan Wood.
The Department of Justice is reportedly supporting Peter Rost's appeal of the prior qui tam case. To quote from the legal brief, "the allegation of a specific false claim is not an absolute prerequisite to pleading a viable FCA claim....The strength of the inference of fraud on the government...
I haven't checked my favorite blogs in quite a while (of course Christina Truelove does every Friday that so we don't have to)....but when I tried to get to Peter Rost's blog, it redirected immediately to the Pfizer corporate web site.
We love the progressive thinking that's going on in pharma. That's why I enjoy my job and what makes covering this side of the industry so much more interesting and positive than looking at the financial side and all the marketing scandals.
Don't turn around. Oh oh. Pharma blogger and author Peter Rost has found a new calling as an Expert Witness for pharma marketing practices). He'd hinted that he'd started exploring this career a few years ago, in an interview he did with Ed Silverman.
John Mack once suggested that some pharma bloggers write about Peter Rost in the hope of "riding in his wake," and increasing their own site traffic and links. It might seem that way, but, let's face it.